Kiora Pharmaceuticals, Inc. KPRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -100.00% |
| Cost of Revenue | -2.31% | 1.76% | -24.15% | -22.94% | -13.71% |
| Gross Profit | 2.31% | -2.28% | -133.39% | -133.25% | -134.73% |
| SG&A Expenses | 6.24% | 2.31% | 3.66% | 10.16% | 8.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.68% | 2.09% | -9.39% | -5.94% | -2.16% |
| Operating Income | -2.68% | -2.30% | -269.50% | -253.17% | -251.27% |
| Income Before Tax | -23.96% | -26.38% | -314.09% | -226.05% | -401.07% |
| Income Tax Expenses | -162.29% | -164.22% | -162.09% | 1,486.71% | 2,198.89% |
| Earnings from Continuing Operations | 8.31% | 8.22% | -401.41% | -253.92% | -474.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.31% | 8.22% | -401.41% | -253.92% | -474.44% |
| EBIT | -2.68% | -2.30% | -269.50% | -253.17% | -251.27% |
| EBITDA | -2.36% | -2.09% | -268.47% | -252.30% | -250.35% |
| EPS Basic | 18.03% | 10.74% | -212.54% | -435.74% | 56.16% |
| Normalized Basic EPS | 5.15% | -6.81% | -167.89% | -272.63% | -64.72% |
| EPS Diluted | 17.93% | 10.74% | -334.52% | -243.37% | 62.99% |
| Normalized Diluted EPS | 5.59% | -6.36% | -211.08% | -2,883.50% | 16.97% |
| Average Basic Shares Outstanding | 19.55% | 5.25% | 7.62% | 38.09% | 91.74% |
| Average Diluted Shares Outstanding | 19.99% | 5.68% | 1.47% | 28.01% | 71.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |